© LB Pharmaceuticals., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Andrew Vaino, Ph.D. has been our Chief Scientific Officer since 2015. Dr. Vaino received his Ph.D. in chemistry from Queen’s University and his MBA from the University of California, Irvine.